HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
DCTD
dCMP deaminase
Chromosome 4 · 4q35.1
NCBI Gene: 1635Ensembl: ENSG00000129187.16HGNC: HGNC:2710UniProt: P32321
37PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
identical protein binding5-hydroxymethyl-dUMP N-hydrolase activityprotein bindingnucleoside salvageovarian neoplasmneurodegenerative diseaseankylosing spondylitispsoriasis
✦AI Summary

DCTD (dCMP deaminase) is a cytoplasmic pyrimidine nucleotide metabolic enzyme that catalyzes the deamination of dCMP to dUMP, providing an essential substrate for thymidylate synthase in dTMP biosynthesis 1. Beyond canonical nucleotide metabolism, DCTD functions in epigenetic nucleotide salvage by catalyzing the first step in a two-step pathway that eliminates 5-hydroxymethyl-dCMP (hmdCMP), an epigenetically modified nucleotide, through deamination to 5-hydroxymethyl-dUMP, which is subsequently hydrolyzed to 5-hydroxymethyluracil 2. Recent investigations have revealed DCTD's role in chemotherapy sensitivity: loss of DCTD confers resistance to the DNA methyltransferase inhibitor decitabine, indicating that 5-aza-dUMP generation contributes to cytotoxicity 3. Additionally, DCTD has been identified as a regulator of ferroptosis in glioblastoma, suggesting therapeutic potential in cancer treatment 4. These findings position DCTD as a critical enzyme at the intersection of nucleotide metabolism, epigenetic regulation, and cancer cell vulnerability, with implications for optimizing nucleoside analogue-based therapies.

Sources cited
1
DCTD catalyzes dCMP deamination to dUMP, providing substrate for thymidylate synthase
PMID: 7685356
2
DCTD catalyzes deamination of 5-hydroxymethyl-dCMP in epigenetic nucleotide salvage pathway
PMID: 33833118
3
Loss of DCTD causes decitabine resistance; 5-aza-dUMP generation contributes to cytotoxicity
PMID: 38760575
4
DCTD regulates ferroptosis in glioblastoma and serves as therapeutic target
PMID: 40917066
⚠Limited data available — This gene has 4 indexed publications. Summary and analysis may be incomplete.
Disease Associationsⓘ20
ovarian neoplasmOpen Targets
0.36Weak
neurodegenerative diseaseOpen Targets
0.27Weak
ankylosing spondylitisOpen Targets
0.13Weak
psoriasisOpen Targets
0.13Weak
type 1 diabetes mellitusOpen Targets
0.13Weak
ocular hypotensionOpen Targets
0.12Weak
Pathologic fractureOpen Targets
0.12Weak
autoimmune diseaseOpen Targets
0.12Weak
autoimmune thyroid diseaseOpen Targets
0.12Weak
celiac diseaseOpen Targets
0.12Weak
common variable immunodeficiencyOpen Targets
0.12Weak
Crohn's diseaseOpen Targets
0.12Weak
juvenile idiopathic arthritisOpen Targets
0.12Weak
systemic lupus erythematosusOpen Targets
0.12Weak
ulcerative colitisOpen Targets
0.12Weak
renal cell carcinomaOpen Targets
0.11Weak
injuryOpen Targets
0.10Suggestive
deficiency anemiaOpen Targets
0.09Suggestive
smoking initiationOpen Targets
0.08Suggestive
osteoarthritis, kneeOpen Targets
0.08Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
NT5C2Protein interaction97%NT5CProtein interaction97%NT5MProtein interaction96%NT5C3AProtein interaction96%NT5C3BProtein interaction95%CDAProtein interaction94%
Tissue Expression6 tissues
Liver
100%
Ovary
79%
Heart
76%
Lung
65%
Brain
58%
Bone Marrow
46%
Gene Interaction Network
Click a node to explore
DCTDNT5C2NT5CNT5MNT5C3ANT5C3BCDA
PROTEIN STRUCTURE
Preparing viewer…
PDB2W4L · 2.10 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
1.92LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF1.50 [0.98–1.92]
RankingsWhere DCTD stands among ~20K protein-coding genes
  • #10,612of 20,598
    Most Researched37
  • #17,435of 17,882
    Most Constrained (LOEUF)1.92
Genes detectedDCTD
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
PMID: 33507815
J Clin Oncol · 2021
1.00
2
Antibody-drug conjugates for cancer therapy.
PMID: 27299281
Lancet Oncol · 2016
0.90
3
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.
PMID: 38906156
Cancer Cell · 2024
0.80
4
Based on network pharmacology, molecular docking and experimental verification to reveal the mechanism of Andrographis paniculata against solar dermatitis.
PMID: 39326136
Phytomedicine · 2024
0.70
5
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
PMID: 34324367
J Clin Oncol · 2021
0.60